Best Practice & Research Clinical Haematology

(The TQCC of Best Practice & Research Clinical Haematology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes64
Molecular markers in ALL: Clinical implications30
COVID-19 disease and immune dysregulation26
Immunologic effects on the haematopoietic stem cell in marrow failure23
CD33 directed bispecific antibodies in acute myeloid leukemia18
Immune checkpoint inhibitors in acute myeloid leukemia17
The promise of macrophage directed checkpoint inhibitors in myeloid malignancies17
Treatment of telomeropathies16
Perspectives on current survival and new developments in AML15
Acute myeloid leukemia and artificial intelligence, algorithms and new scores15
COVID-19 and antiphospholipid antibodies14
CD123 bi-specific antibodies in development in AML: What do we know so far?13
Juvenile myelomonocytic leukemia – A bona fide RASopathy syndrome13
Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax13
Autoimmune disease in CMML-the chicken or the egg?12
Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management12
TCR gene-engineered cell therapy for solid tumors12
Distinguishing constitutional from acquired bone marrow failure in the hematology clinic12
Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome11
COVID-19 and HSCT (Hematopoietic stem cell transplant)11
New targets for CAR T therapy in hematologic malignancies11
Have any strategies in Ph-like ALL been shown to be effective?10
Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia10
Congenital amegakaryocytic thrombocytopenia – Not a single disease10
Controversies in the recent (2016) World Health Organization classification of acute myeloid leukemia9
Incorporating flow cytometry and next-generation sequencing in the diagnosis of CMML. Are we ready for prime?9
Mechanisms of thrombosis in pancreatic ductal adenocarcinoma9
Somatic mosaicism in inherited bone marrow failure syndromes9
Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage9
Toxicities associated with adoptive cellular therapies9
Blood coagulation and cancer genes9
Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?9
GATA2 and marrow failure8
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?8
Thrombosis and bleeding in hematological malignancy7
Molecular genetics of MDS/MPN overlap syndromes7
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents7
WGS and WTS in leukaemia: A tool for diagnostics?7
Clinical experience of CAR T cells for multiple myeloma7
CML - Not only BCR-ABL1 matters6
Atypical CML- the role of morphology and precision genomics6
Overcoming graft failure after haploidentical transplantation: Is this a possibility?6
Clonal hematopoiesis and bone marrow failure syndromes6
Vaccine-induced immune thrombotic thrombocytopenia6
Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?6
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults6
Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults6
Accelerated and blast phase myeloproliferative neoplasms5
Advances in CAR design5
Spliceosomal factor mutations and mis-splicing in MDS5
Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a “catch-all” term?5
Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults5
Challenges in anticoagulation for patients with brain tumors5
Myeloid neoplasms with germline predisposition: Practical considerations and complications in the search for new susceptibility loci5
Myeloproliferative neoplasms in adolescents and young adults5
SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care5
Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?5
Cytogenetics in the genomic era5
Marrow failure and aging: The role of “Inflammaging”5
Bone marrow transplantation for acquired aplastic anemia: What's new5
Antibody based therapy in relapsed acute lymphoblastic leukemia5